» Articles » PMID: 34737227

External Validation of a Refined Four-stratum Risk Assessment Score from the French Pulmonary Hypertension Registry

Abstract

Introduction: Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate risk. Our aim was to validate a four-stratum risk assessment approach categorising patients as low, intermediate-low, intermediate-high or high risk, as proposed by the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) investigators.

Methods: We evaluated incident patients from the French PAH Registry and applied a four-stratum risk method at baseline and at first reassessment. We applied refined cut-points for three variables: World Health Organization functional class, 6-min walk distance and N-terminal pro-brain natriuretic peptide. We used Kaplan-Meier survival analyses and Cox proportional hazards regression to assess survival according to three-stratum and four-stratum risk approaches.

Results: At baseline (n=2879), the four-stratum approach identified four distinct risk groups and performed slightly better than a three-stratum method for predicting mortality. Four-stratum model discrimination was significantly higher than the three-stratum method when applied during follow-up and refined risk categories among subgroups with idiopathic PAH, connective tissue disease-associated PAH, congenital heart disease and portopulmonary hypertension. Using the four-stratum approach, 53% of patients changed risk category from baseline compared to 39% of patients when applying the three-stratum approach. Those who achieved or maintained a low risk status had the best survival, whereas there were more nuanced differences in survival for patients who were intermediate-low and intermediate-high risk.

Conclusions: The four-stratum risk assessment method refined risk prediction, especially within the intermediate risk category of patients, performed better at predicting survival and was more sensitive to change than the three-stratum approach.

Citing Articles

Emerging Gene Therapy Based on Nanocarriers: A Promising Therapeutic Alternative for Cardiovascular Diseases and a Novel Strategy in Valvular Heart Disease.

Yang H, Li J, Song C, Li H, Luo Q, Chen M Int J Mol Sci. 2025; 26(4).

PMID: 40004206 PMC: 11855571. DOI: 10.3390/ijms26041743.


New therapies in pulmonary arterial hypertension: Recent insights.

Guglielmi G, Dimopoulos K, Wort S Int J Cardiol Congenit Heart Dis. 2025; 19:100571.

PMID: 39991439 PMC: 11847046. DOI: 10.1016/j.ijcchd.2025.100571.


Association of insulin resistance surrogates with disease severity and adverse outcomes in chronic thromboembolic pulmonary hypertension: a multicenter cohort study.

Gao L, Zhang S, Li S, Luo M, Lin P, Zhao Z Cardiovasc Diabetol. 2025; 24(1):82.

PMID: 39972493 PMC: 11841354. DOI: 10.1186/s12933-025-02630-x.


Treatment pathways in Finnish patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).

Pentikainen M, Simonen P, Leskela P, Harju T, Jaaskelainen P, Asseburg C Pulm Circ. 2025; 15(1):e12440.

PMID: 39906120 PMC: 11791409. DOI: 10.1002/pul2.12440.


The Clinical Course of Portopulmonary Hypertension and Outcomes With Endothelin Receptor Antagonist Treatment: Observational Study of Data From the US Organ Procurement and Transplantation Network.

DuBrock H, Jose A, Arendse S, Martin N, Studer S, Rosenberg D Transplant Direct. 2025; 10(3):e1586.

PMID: 39877650 PMC: 11774562. DOI: 10.1097/TXD.0000000000001586.


References
1.
Benza R, Farber H, Frost A, Ghofrani H, Corris P, Lambelet M . Application of the REVEAL risk score calculator 2.0 in the PATENT study. Int J Cardiol. 2021; 332:189-192. DOI: 10.1016/j.ijcard.2021.03.034. View

2.
Lewis R, Johns C, Cogliano M, Capener D, Tubman E, Elliot C . Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2019; 201(4):458-468. PMC: 7049935. DOI: 10.1164/rccm.201909-1771OC. View

3.
Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S . Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol. 2020; 73(1):130-139. DOI: 10.1016/j.jhep.2020.02.021. View

4.
Hoeper M, Pausch C, Olsson K, Huscher D, Pittrow D, Grunig E . COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2021; 60(1). PMC: 9260123. DOI: 10.1183/13993003.02311-2021. View

5.
Boucly A, Weatherald J, Humbert M, Sitbon O . Risk assessment in pulmonary arterial hypertension. Eur Respir J. 2018; 51(3). DOI: 10.1183/13993003.00279-2018. View